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Abstract The interleukin-6 (IL-6) receptor complex comprises
the IL-6 receptor (IL-6R, gp80) and the signal transducer gp130.
Binding of IL-6 to its receptor results in dimerization of gp130,
activation of the Jak/STAT pathway, and in a down-regulation
of IL-6 binding sites by endocytosis. The STAT activation after
stimulation is transient, being maximal after 15^30 min and
disappearing after 60^90 min. The mechanism which leads to the
termination of the signal is still unknown.
In this paper we have studied whether the down-modulation of the
STAT signal requires the endocytosis of the receptor complex.
Our results suggest that the desensitization of the IL-6 signal is
not due to internalization of the receptor complex but requires de
novo protein synthesis.
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1. Introduction
Interleukin-6 (IL-6) is a pluripotent cytokine that ^ depend-
ing on the cell type ^ stimulates proliferation, inhibits cell
growth and regulates gene expression (for a recent review
see [1]). The IL-6 receptor complex comprises a speci¢c bind-
ing subunit (IL-6 receptor, gp80) and a signal transducer
gp130. Binding of IL-6 to its cognate receptor triggers dimer-
ization of gp130 which results in the phosphorylation and
activation of Jak1, Jak2 and Tyk2 [1^4]. These kinases phos-
phorylate gp130 on tyrosine residues within its cytoplasmic
domain thereby creating recruitment sites for STAT1/STAT3
and SH2 domain containing phospho-tyrosine phosphatase-2
(SHP-2). STATs are tyrosine-phosphorylated, dimerize and
translocate to the nucleus where they bind to enhancer ele-
ments in the promoter regions of IL-6 responsive genes [1].
The role of SHP-2 in IL-6-dependent signaling is still contro-
versial. It is reported to act as an adapter for the cross-talk to
the MAP kinase pathway which is also involved in a number
of IL-6 responses [5,6]. Furthermore, a limiting e¡ect on IL-6-
dependent gene activation was demonstrated [7].
Binding of IL-6 to gp80 also results in down-regulation of
IL-6 binding sites within 30^60 min via endocytosis of gp80
[8]. We have recently shown that this internalization is medi-
ated via gp130 and strictly dependent on a di-leucine motif
within the gp130 cytoplasmic domain [9]. Whereas internal-
ization of gp80 is ligand-dependent, gp130 undergoes consti-
tutive endocytosis most likely via clathrin coated pits [10].
The STAT activation upon IL-6 stimulation as detected in
an electrophoretic mobility shift assay or a phospho-tyrosine
blot is biphasic. After a rapid activation which is detectable
within a few minutes and peaks around 15^30 min, the STAT
dimer disappears at around 1 h and reappears ^ although to a
lesser extent ^ from 3 h up to 16 h and longer [11]. The
mechanism of the observed down-modulation of the IL-6 sig-
nal after 30 min is unknown. Possible mechanisms involve:
desensitization via (i) endocytosis and down-regulation of
gp80, (ii) activation of a phospho-tyrosine phosphatase such
as SHP-2, and (iii) induction of negative feedback inhibitors
such as suppressors of cytokine signaling (SOCS) and protein
inhibitors of activated STATs (PIAS) [12^16].
In this study we have addressed the question whether endo-
cytosis of gp130 is responsible for the rapid down-modulation
of STAT activation. To answer this question we compared the
kinetics of STAT activation/inactivation in cell lines express-
ing internalization-competent and -de¢cient forms of gp130.
Our results suggest that desensitization of the IL-6 signal is
not mediated via the endocytosis of the IL-6 receptor complex
but requires de novo protein synthesis.
2. Materials and methods
2.1. Cell culture and transfections
HepG2 cells were grown in DMEM/F12 mix supplemented with
10% fetal calf serum, streptomycin (100 mg/l) and penicillin (60 mg/
l). Ba/F3 cells, a murine pre-B lymphocyte line, were cultured in
DMEM containing 10% fetal calf serum and 5% conditioned medium
from X63Ag-653 BPV-mIL-3 myeloma cells as a source of IL-3 [17].
All cells were grown at 37‡C and 5% CO2 in a water-saturated atmo-
sphere.
Ba/F3-gp130 wild-type and mutant cell lines were stably transfected
by electroporation of 28 Wg of pSVLgp130WT or pSVLgp130AA re-
spectively and 2 Wg of pSV2neo into 3.5U106 cells in 0.8 ml medium
at 200 V and 70 ms. Selection with G418 (1 mg/ml) in IL-3-condi-
tioned medium was initiated 24 h after transfection. Selected Ba/F3
clones were screened for the presence of cell surface gp130 by £ow
cytometry.
2.2. Cell surface half-life measurement of gp130
Ba/F3 cells stably expressing human gp130WT and gp130AA were
incubated at 37‡C for di¡erent times in culture medium containing 50
WM cycloheximide to prevent de novo synthesis of gp130. Subse-
quently, the cells were cooled to 4‡C, washed, and cell surface expres-
sion of gp130 was assessed by £ow cytometry.
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2.3. Flow cytometry
Ba/F3-gp130 and Ba/F3-gp130AA cells were harvested, washed, and
resuspended in cold PBS supplemented with 5% fetal calf serum and
0.1% sodium azide (PBS/azide); cells were then ¢xed in 2% parafor-
maldehyde for 20 min on ice. 1U106 cells in 200 Wl of PBS/azide were
incubated with 2 Wg of a gp130 speci¢c monoclonal antibody (mAb)
[18] for 30 min, washed twice, and the gp130-bound antibodies visu-
alized using a 1:50 dilution of an R-phycoerythrin-conjugated anti-
mouse IgG-F(abP)2 (Dianova) for 30 min on ice. Subsequently, cells
were washed and resuspended in PBS/azide. 2U104 cells/sample were
analyzed using a FACScalibur (Becton Dickinson). Mean £uorescence
intensity (MFI) was recorded and used in the calculation of percent
antibody binding. Speci¢c binding was calculated by subtracting the
base line cell £uorescence intensity which was determined with cells
incubated solely with the secondary antibody from the £uorescence
intensity obtained with both, primary and secondary antibodies:
(MFI of cycloheximide treatment) divided by (MFI of cells at time
point 0)U100.
2.4. Cell lysis and immunoprecipitations
For immunoprecipitations of SHP-2, Ba/F3-gp130 and Ba/F3-
gp130AA cells were stimulated with IL-6 (20 ng/ml) and sIL-6R
(1 Wg/ml) for 0^120 min and lysed in 1 ml of lysis bu¡er (50 mM
Tris, pH 7.4; 150 mM sodium chloride; 1 mM EDTA; 0.5% Nonidet
P-40; 1 mM sodium £uoride; 15% glycerol; 1 mM sodium vanadate;
0.5 mM EDTA; 0.25 mM PMSF; 5 Wg/ml aprotinin; 1 Wg/ml leupep-
tin; 1 Wg/ml pepstatin). 1 Wg of a polyclonal anti-SHP-2 antiserum was
then added to the lysates at 4‡C for 18 h to precipitate SHP-2. After
incubation with protein A-sepharose (2.5 mg/ml lysis bu¡er) for 1 h at
4‡C, the samples were washed with washing bu¡er (50 mM Tris, pH
7.4, 150 mM sodium chloride, 15% glycerol, 1 mM EDTA, 0.5%
Nonidet P-40), boiled in reducing sample bu¡er and separated on a
10% SDS^polyacrylamide gel.
2.5. Western blotting and immunodetection
The electrophoretically separated proteins were transferred to poly-
vinylidene di£uoride membranes by the semi-dry Western blotting
method. Non-speci¢c binding was blocked with 10% bovine serum
albumin in TBS-N (20 mM Tris/HCl, pH 7.4, 137 mM NaCl, 0.1%
Nonidet P-40) for 20 min. Phosphorylation of SHP-2 was detected by
an anti-phospho-tyrosine antibody (4G10) (Upstate Biotech) at a con-
centration of 1 Wg/ml in TBS-N for 1 h. After extensive rinsing with
TBS-N, the immunoblots were incubated for 1 h with a horseradish
peroxidase-conjugated goat anti-mouse IgG secondary antibody. The
immunoblots were developed using the enhanced chemiluminescence
system (ECL, Amersham Pharmacia Biotech) according to the man-
ufacturer’s instructions.
2.6. Electrophoretic mobility shift assay (EMSA)
Ba/F3-gp130, Ba/F-gp130AA, and HepG2 cells were grown for 2^3
days and stimulated with IL-6 for di¡erent times. Nuclear extracts
were prepared as described [19]. The protein concentration was deter-
mined with a Bio-Rad1 protein assay. EMSAs were performed as
described previously using a double-stranded 32P-labelled mutated
m67SIE oligonucleotide from the c-fos promoter (m67SIE: 5P-GAT
CCG GGA GGG ATT TAC GGG GAA ATG CTG-3P) [20]. The
protein^DNA complexes were separated on a 4.5% polyacrylamide gel
containing 7.5% glycerol in 0.25-fold TBE at 20 V/cm for 4 h. Gels
were ¢xed in 10% methanol, 10% acetic acid and 80% water for 1 h,
dried and autoradiographed.
3. Results
HepG2 cells were stimulated with IL-6 at 1 Wg/ml and the
time-course of STAT activation was monitored over 16.5 h
employing an electrophoretic mobility shift assay (Fig. 1, left
panel). A strong STAT3 signal was detected after 30 min that
disappeared almost completely after 1.5 h. At later time points
a second, less intensive wave of activation was seen until 16.5 h
con¢rming previous observations that STAT activation after
IL-6 is biphasic [11]. We have shown that in HepG2 cells
within 60 min IL-6 binding sites are down-regulated after
stimulation with saturating amounts of IL-6 [8], raising the
possibility that the observed down-modulation of STAT ac-
tivity after 1.5 h is due to the depletion of plasma membrane
IL-6R (gp80). In order to test this, we stimulated HepG2 cells
with IL-6 and 2 Wg/ml of recombinant soluble IL-6R and
again monitored the kinetics of STAT activation/inactivation.
The soluble IL-6R in combination with IL-6 acts agonistically
on cells expressing gp130 [21]. As shown in Fig. 1 (right pan-
el), the STAT signal over the whole time-course is increased
under these conditions so that even STAT1 is now promi-
nently activated. This is most likely due to a surplus of
gp130 over IL-6R molecules at the plasma membrane of
HepG2 cells [21]. However, this activation pattern is still bi-
phasic and qualitatively not di¡erent from the one in the left
panel. We have recently demonstrated that gp130 is endocy-
tosed constitutively and not down-regulated by stimulation
via IL-6/sIL-6R [10]. In addition, although the complex of
IL-6 and sIL-6R is internalized by HepG2 cells [22], only
marginal amounts of this complex will be depleted from the
culture medium within 1 h. Thus, at 1.5 h of stimulation
gp130 and IL-6/sIL-6R are still present at the cell surface,
nevertheless the signal is turned-o¡ as well. Therefore, we
conclude that endocytosis of the IL-6 receptor complex might
not be the crucial process for the observed down-modulation
of STAT activation.
In order to further analyze the relationship between endo-
cytosis and signal desensitization, studies with murine Ba/F3
pre-B cells stably transfected with gp130WT and gp130AA ^ in
which the di-leucine internalization motif was replaced by two
alanines [9] ^ were performed. In transfected Ba/F3 cells,
gp130WT but not gp130AA is e⁄ciently internalized as assessed
by £ow cytometry (Fig. 2a). As shown in Fig. 2b, the biphasic
STAT activation pattern is observed in both cell lines after
stimulation with IL-6/sIL-6R. The quantitative di¡erence of
the initial STAT activation between Ba/F3-gp130WT and Ba/
F3-gp130AA is due to the increased surface expression of
gp130AA (data not shown). In addition, phosphorylation of
SHP-2 was compared in these two cell lines (Fig. 2c). Also
SHP-2 is only transiently phosphorylated and no di¡erence
was observed in activation of SHP-2 in these two cell lines.
Additional experiments were performed in A375 melanoma
cells stably expressing internalization-competent and -de¢cient
forms of EPO receptor/gp130 chimeras. In these cells, ac-
tivation of the Jak/STAT pathway results in an inhibition
of proliferation [23,11]. After EPO stimulation, STAT and
Fig. 1. Transient STAT activation of HepG2 cells after stimulation
with IL-6 (left panel) and IL-6/sIL-6R (right panel). HepG2 cells
were stimulated with 1 Wg/ml IL-6 or 1 Wg/ml IL-6 and 2 Wg/ml sIL-
6R respectively for the indicated time and nuclear extracts were pre-
pared. EMSAs were performed with the labelled m67SIE probe.
The positions of the three dimers formed are indicated.
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SHP-2 activation were comparable in A375 cells expressing
internalization-competent and -de¢cient receptor chimeras
and in both cell lines proliferation was inhibited to the same
extent (data not shown). Taken together, our results strongly
suggest that endocytosis is not the mechanism of down-mod-
ulation of STAT activity.
Recently, it was demonstrated that proteins of the SOCS
family are negative feedback regulators of cytokine signaling
[14^16]. These proteins are induced by cytokines and bind to
the receptors and the Jaks, respectively, thereby inhibiting
their activity. If these or related proteins are involved in the
STAT desensitization observed in di¡erent cell systems, this
down-modulation should be sensitive to inhibitors of de novo
mRNA and protein synthesis. We addressed this question us-
ing the Ba/F3-gp130AA cells. These cells are especially useful
for this study since inhibition of protein synthesis in these cells
does only marginally (25%) a¡ect gp130 surface expression
(Fig. 2a). In contrast, in gp130WT expressing cells, gp130 sur-
face protein levels are rapidly declining after cycloheximide
due to the constitutive internalization and short half life of
this protein (Fig. 2a). As shown in Fig. 3, stimulation of Ba/
F3-gp130AA cells with IL-6/sIL-6R in the presence of cyclo-
heximide resulted in a sustained STAT activation over the
whole 4 h time-course. Thus, we conclude that (a) de novo
synthesized protein(s) are responsible for the down-modula-
tion of STAT activity after the initial activation peak.
4. Discussion
Cytokines and growth factors elicit their intracellular sig-
nals via plasma membrane receptors that usually activate
phosphorylation cascades ultimately leading to altered growth
behavior or gene expression. Receptor activation has to be
spatially and temporally controlled in order to avoid over-
stimulation that might result in cell transformation and tumor
growth. Therefore, e⁄cient mechanisms to turn-o¡ a signal
cascade must exist. Means to desensitize an activated receptor
are: (i) phosphorylation or dephosphorylation, (ii) transloca-
tion into endosomes via its internalization, (iii) increased deg-
radation or diminished synthesis, and (iv) induction of nega-
tive feedback inhibitors [12^16,24].
In this study we have studied possible mechanisms which
are responsible for the rapid attenuation of Jak/STAT signal-
ing after the initial trigger by the IL-6 signal transducer
gp130. We focussed on the role of endocytosis in this process
since the observed desensitization is parallel in time to the
endocytosis and down-regulation of gp80 [8]. Furthermore,
Fig. 2. a: Cell surface half lives of gp130WT or gp130AA in stably
transfected Ba/F3 cells. Cell surface expression on cells treated for
di¡erent times with 50 WM cycloheximide was assessed by £ow cyto-
metry using an anti-gp130 monoclonal antibody. Time 0 corre-
sponds to a 30 min incubation in cycloheximide containing medium,
since this is the time required for newly synthesized gp130 to reach
the cell surface [19]. Antibody binding was calculated as described
in Section 2. The means and S.D. of three independent experiments
are shown. b: STAT activation of stably transfected Ba/F3 cells ex-
pressing gp130WT and gp130AA after stimulation with IL-6/sIL-6R.
The cells were stimulated with 20 ng/ml IL-6 and 1 Wg/ml sIL-6R
for the indicated time and nuclear extracts were prepared. EMSAs
were performed with the labelled m67SIE probe. The positions of
the three dimers formed are indicated. c: Kinetics of SHP-2 phos-
phorylation in stably transfected Ba/F3 cells expressing gp130WT
and gp130AA. Cells were stimulated with 20 ng/ml IL-6 and 1 Wg/ml
sIL-6R, lysed and immunoprecipitations using an anti-SHP-2 antise-
rum were performed as described in Section 2. Aliquots were sepa-
rated on an SDS gel and the immunoblot was developed using an
anti-phospho-tyrosine monoclonal antibody and reprobed with an
anti-SHP-2 antiserum. The prominent band at 100 kDa most likely
represents Gab-1 [32].
Fig. 3. STAT activation of Ba/F3-gp130AA cells. The cells were
treated for di¡erent times with 50 WM cycloheximide or left un-
treated and stimulated with 20 ng/ml IL-6 and 1 Wg/ml sIL-6R for
the indicated time and nuclear extracts were prepared. EMSAs were
performed with the labelled m67SIE probe. The positions of the
three dimers formed are indicated.
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recent experiments had revealed that truncated gp130 chime-
ras which still contain a STAT recruitment site but lack an
internalization motif result in a prolonged STAT activation
[11]. This suggested that attenuation of the signal requires
internalization. However, these mutants also lacked a recruit-
ment site for SHP-2, a tyrosine phosphatase that possibly is
also involved in desensitization [7]. The results of this study
unequivocally demonstrate that endocytosis is not necessary
for attenuation to occur. This was ¢rst demonstrated in hep-
atoma cells HepG2, where the desensitization not only was
observed after stimulation with IL-6 but also after IL-6/sIL-
6R treatment (Fig. 1). In the latter case the down-regulation
of the plasma membrane IL-6R is compensated by the large
excess of agonistic soluble receptor complexes. Since surface
gp130 is not down-regulated by ligation [10] and thus present
at the cell surface at all times, signaling-competent receptor
complexes still can be formed. Therefore, other mechanisms
than IL-6R down-regulation have to be responsible for desen-
sitization. This conclusion is further supported by our ¢ndings
that signal attenuation even occurs after stimulation of inter-
nalization-de¢cient gp130. These were created by replacing the
crucial di-leucine residue of the internalization motif by ala-
nines, a mutation that strongly reduces the internalization
capability of gp130 ([9,25] and this study (Fig. 2). However,
no e¡ect on the time-course of signal attenuation was ob-
served with gp130AA.
Similar ¢ndings were obtained in A375 melanoma cells that
express an EPOR/gp130WT or EPOR/gp130AA chimeric recep-
tor [11] (data not shown). Neither STAT nor SHP-2 phos-
phorylation nor EPO-induced cell growth inhibition were dif-
ferent. Thus, signal generation as we have previously shown
[25] as well as signal termination (this study) are independent
of the endocytosis of gp130. Since signaling also does not
a¡ect the rate of gp130 endocytosis, we conclude that signal-
ing and internalization of the IL-6 receptor complex are not
interdependent. In this respect, gp130 behaves more like G-
protein linked receptors such as the L2-adrenergic receptor or
the neurokinin receptor-1 than like receptor tyrosine kinases
such as the epidermal growth factor receptor [26]. The L2-
adrenergic receptor is e⁄ciently internalized after ligand bind-
ing but neither inhibitors of endocytosis nor mutations within
the receptor that prevent agonist-induced endocytosis a¡ect
homologous desensitization [27,28]. In contrast, the EGF re-
ceptor signaling is uniformally enhanced in cells in which
endocytosis via clathrin coated pits is blocked by over-expres-
sion of a dominant-negative form of dynamin [24] and EGF
receptors with a point mutation of the kinase domain that
abolishes kinase activity are only internalized at a basal rate
[29].
What then is the mechanism of gp130 desensitization? The
tyrosine phosphatase SHP-2 is known to be recruited to tyro-
sine 759 of gp130 after phosphorylation by Jaks of this resi-
due. Mutation of Tyr-759 leads to a loss of SHP-2 recruitment
and results in an enhanced transcription of reporter genes [7].
However, in cell lines expressing wild-type gp130 or the Tyr-
759 mutant the time-course of STAT activation and inactiva-
tion is similar although it di¡ers in a quantitative fashion. At
1.5 h the signal in both cell lines is strongly down-regulated.
Thus, SHP-2 is also not the determining factor in gp130 de-
sensitization. Haspel et al. reported on the inactivation of
STAT1 by a nuclear protein tyrosine phosphatase [30,31].
However, the identity of this phosphatase and its regulation
are presently unknown. Furthermore, it is not clear whether
this phosphatase also dephosphorylates STAT3.
Ba/F3-gp130AA cells stimulated with IL-6/sIL-6R displayed
a sustained STAT activation in the presence of cycloheximide.
This suggests that de novo synthesized proteins are responsi-
ble for the down-modulation of STAT activity. In this respect,
it is interesting that two classes of inhibitors for Jak/STAT
signaling have recently been discovered, the SOCS proteins
and PIAS-1/PIAS-3. SOCS are a growing family of immediate
early genes that are rapidly transcribed after STAT activation
and code for proteins that inhibit the Jak/STAT pathway by
direct interaction with the receptors or active Jaks thereby
creating a negative feedback loop [14^16]. PIAS-1/PIAS-3
are proteins that directly bind activated STAT1/STAT3 and
inhibit their binding to cognate DNA elements [13]. Whether
and how PIAS activity is regulated is currently unknown. Our
¢nding that inhibition of protein synthesis completely abol-
ishes signal attenuation makes it likely that members of
the SOCS family are responsible for this down-modulation
(Fig. 3).
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